key: cord-0926590-q71pgufb
authors: Wang, Junzhi
title: A bivalent recombinant vaccine: a promising strategy against both SARS-CoV-2 variants and wild type of the virus
date: 2021-07-17
journal: Signal Transduct Target Ther
DOI: 10.1038/s41392-021-00691-4
sha: b9792c26a09915b8424c68f6f4e71d8b00311295
doc_id: 926590
cord_uid: q71pgufb

nan

from S1-WT immunized mice showed protective effects against wild-type, D614G, B.1.1.7 pseudoviruses but significantly decreased protection against B.1.351 and P.1. In contrast, sera from S1-Mut immunized mice showed higher protection against B.1.351 and P.1 than wild-type and B.1.1.7 pseudoviruses, suggesting the weakened cross-protection of S1-WT and S1-Mut against wild-type and mutant strains (Fig. 1 ). These results are consistent with the previous reports that the mutations in spike protein, especially in RBD, could induce immune escape, increase the binding of the virus to ACE2, and decrease the efficacy of vaccines based on non-mutant SARS-CoV-2, which indicates that the development of a universal vaccine is extremely urgent. 4, 5 Next, to explore a vaccine exerting strong protection against both wild-type and mutant strains of SARS-CoV-2, the authors combined the recombinant S1-WT and S1-Mut proteins to form a bivalent vaccine. Further, they found that the bivalent vaccine demonstrated cross-protection against wild-type and mutant SARS-CoV-2, which indicates that the bivalent vaccine might be a candidate as a universal vaccine against SARS-CoV-2 and mutant strains (Fig. 1) . And the safety of the bivalent vaccine was good in mice. Despite the lack of data from other models, these results are still encouraging and might provide a promising strategy to explore the potential clinical use of the bivalent recombinant vaccine to prevent the COVID-19 pandemic in the future.

Taken together, the study by He and colleagues highlights the immunoprotection of wild-type and mutant S1 proteins in hACE2 mice, and points that the monovalent recombinant protein vaccines are not universal for both SARS-CoV-2 and mutant strains. Moreover, the authors suggest the bivalent vaccine as a potential strategy, which shows excellent neutralization against wild-type and mutant pseudoviruses. Critically, the authors used various pseudoviruses rather than viruses to determine the neutralization property of these recombinant proteins, which may not precisely represent the data profile in live viruses. Therefore, further studies are warranted to characterize the protective role of the bivalent vaccine in nonhuman animals against SARS-CoV-2 and mutant strains. The authors were devoted to exploring cross-protective bivalent fusion vaccines that consist of wild-type and mutant spike protein fragments, which might be another approach to prevent SARS-CoV-2 and mutant strains. Nevertheless, it is very appealing to concentrate on this promising strategy to explore universal coronavirus vaccine against both SARS-CoV-2 and mutant strains. The further development and application of the universal coronavirus vaccine may offer an effective, promising Fig. 1 The diagram of monovalent recombinant S1-WT and S1-Mut protein vaccine and the combined bivalent vaccine against SARS-CoV-2 and mutant strains. The ICR-hACE2 mice were immunized with recombinant S1-WT/S1-Mut protein vaccine and bivalent vaccine by intramuscular injection on days 0, 14, and 28, separately. The S1-WT vaccine induced higher neutralizing antibodies against wild-type of SARS-CoV-2 than that of variants while S1-Mut vaccine stimulated higher neutralizing antibodies against SARS-CoV-2 variants. The bivalent recombinant vaccine composed of S1-WT and S1-Mut could induce the neutralizing antibodies against both SARS-CoV-2 variants and wildtype of the virus, indicating a potential and effective approach for the development of universal coronavirus vaccine

A bivalent recombinant vaccine targeting the S1 protein induces neutralizing antibodies against both SARS-CoV-2 variants and wild-type of the virus

Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy

Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons. org/licenses/by/4.0/.